Tociluzumab

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Chronic Granulomatous DiseaseRelapsed or Refractory Follicular Lymphoma

14 competitors in Chronic Granulomatous Disease

#DrugCompanyPhaseTrials

1

Advil

KKenvue Brands

Approved

—2

Busulfex

Akero Therapeutics

Phase 2

53

Cytoxan

BBaxter Healthcare Corporation

Phase 2

44

Campath

GGenzyme, a Sanofi Company

Phase 2

35

Rapamune

PPrism Pharmaceuticals

Phase 2

36

Tociluzumab

Roche

Phase 3

17

Xeljanz

Pfizer

Phase 2

18

Actimmune

HHorizon Therapeutics Ireland DAC

Preclinical

19

Emapalumab-Izsg

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 2

110

JSP191

JJasper Therapeutics, Inc.

Phase 1

1Show 1 more competitor

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Chronic Granulomatous Disease1 trial

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT05463133·50 enrolled

Relapsed or Refractory Follicular Lymphoma1 trial

Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a Non-Randomized Single Arm US Extension of Mosunetuzumab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy

Active, not recruiting·Roche·Phase 3·NCT04712097·478 enrolled

Details

Drug Info

Related News